This segment focuses on the research, development, manufacturing, and commercialization of the Impella family of percutaneous heart pumps. These devices, including Impella 2.5, CP, 5.0, LD, 5.5, and RP, provide circulatory support to patients with various heart conditions, including those undergoing high-risk PCI and those in cardiogenic shock. Research and development efforts are focused on improving pump performance, ease of use, and expanding the range of applications. Technologies include miniaturized motors, integrated sensors, and advanced algorithms for optimized patient management. The Impella pumps have a significant impact on patient outcomes by improving survival rates and reducing complications in critical cardiac cases. Abiomed's market position is strong, with a focus on innovation and clinical data to support the use of Impella. Future opportunities include expanding into new markets and developing next-generation pumps. Regulatory and clinical aspects are critical, with ongoing clinical trials and FDA approvals. Partnerships with hospitals and physicians are essential for successful adoption and patient care.

This segment encompasses the development and commercialization of technologies that enhance the use and effectiveness of Impella heart pumps. This includes the Impella SmartAssist platform, which utilizes optical sensor technology and algorithms to improve pump positioning and native heart assessment during weaning. It also includes Impella Connect, a cloud-based technology that enables remote monitoring of the Automated Impella Controller. Research and development efforts focus on improving the user experience, providing real-time data and insights to clinicians, and optimizing patient management. The technologies leverage advanced sensor technology, data analytics, and secure cloud computing. These technologies improve patient outcomes by enabling more precise pump placement, facilitating better patient monitoring, and streamlining clinical workflows. Abiomed's market position is strengthened by these value-added technologies, which differentiate its products and enhance the overall patient care experience. Future opportunities include integrating these technologies with other medical devices and expanding their functionality. Regulatory and clinical aspects are important, with a focus on data security and clinical validation. Partnerships with hospitals and technology providers are key to successful implementation and adoption.

This segment focuses on the development and commercialization of devices and technologies that provide advanced circulatory and respiratory support. This includes the OXY-1 System, a portable external respiratory assistance device, and the ongoing development of new products such as Impella ECP, Impella XR Sheath, and Impella BTR. Research and development efforts are focused on expanding the range of circulatory support solutions, improving device performance, and addressing unmet clinical needs. Technologies include advanced pump designs, biocompatible materials, and innovative respiratory support systems. These technologies aim to improve patient outcomes by providing comprehensive support for patients with severe heart and lung conditions. Abiomed's market position is enhanced by its commitment to innovation and its ability to offer a broad portfolio of circulatory support solutions. Future opportunities include expanding into new therapeutic areas and developing next-generation devices. Regulatory and clinical aspects are critical, with a focus on obtaining FDA clearance and conducting clinical trials. Partnerships with hospitals, research institutions, and technology providers are essential for successful product development and commercialization.